Oxygenta Pharmaceutical Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
For the full year, sales was INR 396.42 million compared to INR 309.88 million a year ago. Revenue was INR 396.85 million compared to INR 310.05 million a year ago. Net loss was INR 34.79 million compared to INR 115.71 million a year ago. Basic loss per share from continuing operations was INR 1.09 compared to INR 8.15 a year ago. Diluted loss per share from continuing operations was INR 1.04 compared to INR 8.15 a year ago.